Best Infectious Diseases Companies in Switzerland
The 51 best Infectious Diseases companies in Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Memo Therapeutics.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Switzerland
| # | Company | Disclosed funding | Last round | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Memo Therapeutics Developer of antibodies for treating infectious diseases and cancer | $97M | 26 mo ago | 21 | — | — | 52 patents Therapeutic antibodies targeting BK virus and SIGLEC‑9, plus immunoreceptor gene recovery | 1 partnership |
| 2 | ArpIda Developer of drugs for the treatment of microbial resistance | $90M | 261 mo ago | 45 | — | — | 104 patents Antimicrobial drug compounds (benzofurans, 2H‑chromenes, diphenyl ureas) and their manufacturing processes | — |
| 3 | Bioversys Developer of therapeutics for Antimicrobial Resistance | $62M | 43 mo ago | 24 | Marc Gitzinger Founder & CEO | 7 signals ▼22% Board | 233 patents Rifabutin antibiotic analogs and lyophilized formulations for anti‑tuberculosis therapy | — |
| 4 | NewBiologix Provider of engineered cell lines for drug development | $50M | 38 mo ago | — | Nicolas Mermod Co-Founder | — | — | — |
| 5 | LimmaTech Biologics Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques | $40M | 29 mo ago | 40 | — | — | 37 patents Glycoengineered vaccine antigens and therapeutic glycoproteins for bacterial pathogens | — |
| 6 | Vaxxilon Developer of synthetic carbohydrate vaccines for drug-resistant infectious diseases | $33M | 83 mo ago | 17 | — | — | 31 patents Design of synthetic polysaccharide‑protein conjugate vaccines for bacterial pathogens | — |
| 7 | GlycoVaxyn Developer of bioconjugate vaccines to treat a range of bacterial infections | $32M | 209 mo ago | 21 | Michael Wacker Co-Founder | — | 147 patents Engineered bacterial glycoprotein and polysaccharide conjugate vaccines for infectious disease prevention | — |
| 8 | Vector BioPharma Developer of gene delivery platform to treat various disease conditions | $30M | 47 mo ago | 39 | Lorenz Mayr Co-Founder | — | 7 patents Targeted adenoviral gene‑delivery platforms for immune‑cell therapies and vector production | — |
| 9 | Abionic Provider of point-of-care diagnostic tool for allergy profiles | $29M | 100 mo ago | 53 | Iwan Märki Co-Founder & CTO | — | 56 patents Patents concentrated in transport & manufacturing processes | — |
| 10 | Lumavita Developer of small molecule therapeutics for gynecological infections | $22M | 205 mo ago | — | Cees Winnips Co-Founder & CSO | — | 22 patents High-purity pentamycin antibiotic purification and formulation processes | — |
| 11 | Virometix Vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases (both bacterial… | $19M | 8 mo ago | 15 | Anna Sumeray CEO | — | 41 patents Peptide-based vaccine antigens and lipopeptide VLP platforms for RSV and pneumococcus | — |
| 12 | FIND Diagnostics Diagnostic tests for poverty-related diseases | $15M | 46 mo ago | 501 | William Rodriguez CEO | — | — | 1 partnership |
| 13 | AmVac Vaccine developer for the treatment of infections and urogenital conditions | $15M | 157 mo ago | 11 | Ali Pashazadeh CEO | — | 29 patents Recombinant negative‑strand RNA viral vectors for heterologous protein expression and RSV semi‑live vaccines | — |
| 14 | Resistell Provider of antibiotic susceptibility testing | $13M | 43 mo ago | 31 | — | — | 8 patents Micro/nano particle motion analysis and bio‑functionalized cantilever sensing technologies. | — |
| 15 | Kenta Biotech Developing human monoclonal antibodies for the prevention and treatment of bacterial and viral infections | $10M | 208 mo ago | 11 | — | — | 46 patents Therapeutic and diagnostic human monoclonal antibodies for S. aureus alpha‑toxin and P. aeruginosa LPS serotypes | — |
| 16 | Rqmicro Developer of instruments, reagents, and kits for rapid pathogen detection | $6M | 64 mo ago | 14 | Hans-Anton Keserue Founder & CEO | — | 18 patents Patents concentrated in transport & manufacturing processes | — |
| 17 | Viroblock Specialty company developing antiviral products for enveloped viruses | $5M | 173 mo ago | 9 | — | — | 26 patents Lipid-based antiviral formulations that inactivate enveloped viruses and inhibit gram‑positive bacteria. | — |
| 18 | RocketVax Developer of therapeutic solutions for the treatment of SARS-CoV-2 | $4M | 41 mo ago | 6 | — | — | 24 patents Attenuated SARS‑CoV‑2 viral vectors and synthetic long‑chain nucleic acids for coronavirus vaccines | — |
| 19 | Relief Therapeutics Developer of drugs for treating pulmonary and infectious diseases | $3M | 24 mo ago | 69 | — | 3 signals ▼70% M&A | — | — |
| 20 | Avelo Developer of a breath aerosol diagnostic device for respiratory infections | $2M | 46 mo ago | 8 | Tobias Broger Co-Founder | 5 signals ▲150% Announcements | 6 patents Collecting and analyzing exhaled aerosol particles for respiratory diagnostic testing | 1 partnership · 1 award |
| 21 | Mymetics Virosome-based prophylactic vaccines for viral infections | $2M | 135 mo ago | 8 | — | — | 42 patents Oral virosome-based vaccine formulations for mucosal immunization | — |
| 22 | Redbiotec Multiprotein assemblies as prophylactic vaccines against infectious diseases | $2M | 140 mo ago | 12 | Corinne John Co-Founder | — | 42 patents HSV therapeutic vaccines and recombinant host cell production of casein proteins | — |
| 23 | Inositec Developer of therapeutics for soft tissue calcification disorders | $1M | 117 mo ago | 6 | — | — | 8 patents Inhibiting renal calcium oxalate stone formation using inositol phosphate analogs | — |
Top 12 Infectious Diseases companies in Switzerland
#1
Series C · Zurich, Zurich · founded 2009 · 15 employees$18.9Mraised▾
Virometix is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. Rational molecular design, chemical synthesis and Virometix's proprietary Synthetic Virus-Like Particle platform technology allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability. Virometix Vaccines is a spin-out company from the University of Zurich.
- Nov 2025Series C$15M
- Jul 2020Series B$8M
- Sep 2017Series A$1.3M
- May 2017Series A$5.1M
#2
Series C · Schlieren, Zurich · founded 2012 · 21 employees$97.2Mraised▾
Developer of antibodies for treating infectious diseases and cancer. The company has developed its proprietary microfluidic single-cell molecular cloning and screening technologies for the production of antibodies. The company's lead candidate is used to treat infectious diseases.
- May 2024Series C$22.1M
- Nov 2023Series C$27.5M
- Feb 2022Series B$24.9M
- Dec 2021Grant (prize money)$11.4M
#3
Acquired · Schlieren, Zurich · founded 2015 · 40 employees$40Mraised▾
LimmaTech Biologics is a clinical stage biopharmaceutical company focused on the development and manufacture of bioconjugate vaccines using glycoengineering and protein glycosylation techniques previously developed by GlycoVaxyn and now owned by GSK. The company was founded as a spin-off of GlycoVaxyn, which was acquired by GSK in February 2015 following a two-year collaboration. The proprietary bioconjugation platform is claimed to offer potential solutions to many issues associated with the chemical conjugation process - expanding the range of indications, enabling large scale manufacture at low cost. LimmaTech is developing vaccines exclusively for GSK and actively exploring applications of glycoengineering and protein glycosylation technology in other fields.
- Feb 2024Grant (prize money)$2.2M
- Feb 2024Series A$3M
- Oct 2023Seed—
- Oct 2023Series A$37M
#4
Public · Basel, Basel Stadt · founded 2008 · 24 employees$62.5Mraised▾
Developer of therapeutics for Antimicrobial Resistance. The company is focused on developing and commercializing antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. The company's pipeline includes BV100 for Acinetobacter baumannii and Alpibectir for tuberculosis.
- Jan 2023Series C$9M
- Jun 2022Series C$25.1M
- Jun 2021Grant (prize money)$4.3M
- Apr 2021Venture Debt$23.8M
#5
Public · Geneva, Geneva · founded 2013 · 69 employees$2.8Mraised▾
Developer of drugs for treating pulmonary and infectious diseases. The company's lead candidate is RLF-100 a synthetic human vasoactive intestinal peptide (VIP) for respiratory indications. It is currently focused on COVID-19-induced severe lung injury and pulmonary sarcoidosis. Another drug candidate ACER-001 is being developed for the treatment of two rare and debilitating diseases including Urea cycle disorders and Maple syrup urine disease.
- Aug 2024Post IPO—
- Jun 2023Post IPO—
- Aug 2021Post IPO$16.4M
- Mar 2021Post IPO$10.8M
#6
Seed · Epalinges, Vaud · founded 2022$50Mraised▾
Provider of engineered cell lines for drug development. It offers DNA-based platform for the production of recombinant adeno-associated virus (rAAV) vectors, human and mammalian cell lines to produce advanced therapy medicinal products.
- May 2023Seed$50M
#7
Deadpooled · Basel, Basel Stadt · founded 2021 · 39 employees$30Mraised▾
Developer of gene delivery platform to treat various disease conditions. The company develops next-generation therapeutics using proprietary engineered adenoviral vectors focused on immuno-oncology.
- Aug 2022Series A$30M
#8
Series B · Basel, Basel Stadt · founded 2017 · 31 employees$13.4Mraised▾
Provider of antibiotic susceptibility testing. It offers a culture-based antibiogram and allows for diagnosis based on the detection of movement caused by living bacterial cells. Resistell helps in knowing which antibiotic should be taken by a patient and in what concentration it should be administered.
- Dec 2022Series B$9.1M
- Apr 2022Grant (prize money)—
- Aug 2020Grant (prize money)$2.9M
- Jul 2020Grant (prize money)$2.8M
#9
Funding Raised · Geneva, Geneva · founded 2003 · 501 employees$15.3Mraised▾
FIND is a global non-profit organization engaged in the development, evaluation, and delivery of high-quality, affordable diagnostic tests for poverty-related diseases, including TB, malaria, HIV/AIDS, sleeping sickness, hepatitis C, Chagas disease, etc., as well as infectious diseases with outbreak potential, such as Ebola. FIND operates as a product development partnership with active collaborations with over 150 organizations including government ministries, academic centers, commercial entities, NGOs and PPPs. Intellectual property developed and owned by FIND is commercialized in partnership with commercial entities in a manner that ensures that benefits are passed on to patients in resource-poor settings, while distribution rights for high-income countries and the private sector in developing countries are retained by the industry partner.
- Oct 2022Grant (prize money)$27.3K
- Jan 2019Grant (prize money)$290.1K
- Sep 2010Grant (prize money)$15M
#10
Acquired · Reinach, Basel Landschaft · founded 1997 · 45 employees$90.4Mraised▾
Arpida (SIX: ARPN) is a biopharmaceutical company headquartered in Reinach, near Basel, Switzerland with operations in Switzerland and the USA. It focuses on novel drugs that seek to overcome the growing problem of microbial resistance. Arpida's leading product candidate is intravenous iclaprim, an antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
#11
Series A · Reinach, Basel Landschaft · founded 2015 · 17 employees$33Mraised▾
Developer of synthetic carbohydrate vaccines for drug-resistant infectious diseases. The company has proprietary technology based on the research on parts of the sugar coating of the bacteria that are actually necessary to trigger an immune response. It is advancing vaccine candidates using homogeneous, synthetically produced carbohydrate antigens and novel carrier molecules for the prevention of infectious diseases.
- Aug 2019Grant (prize money)$1.4M
- Jun 2015Series A$33M
#12
Series C · Epalinges, Vaud · founded 2010 · 53 employees$28.9Mraised▾
Abionic is a provider of point-of-care diagnostic tool for allergy profiles. It focussed on developing diagnostic tools for allergies. It has developed products such as the abioSCOPE (the reader), a biomedical screening device for measuring the concentration of immunoglobulin protein E (IgE) to obtain an allergy profile and the abioGUIDE, an application for smartphones and tablets to see the reports. It also developed a Screening capsule that provides information about the respiratory allergies of the patients from one drop of blood.
- Mar 2018Series C$21.1M
- Oct 2014Series B$4M
- Apr 2012Series A$3.7M
- Oct 2010Seed$127.8K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Diagnostics is moving in Switzerland
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 806 Switzerland-affiliated papers.
- FIND167
- Swiss Tropical and Public Health Institute95
- University of Basel71
- Foundation for Innovative New Diagnostics50
- University Hospital of Basel46
- Point-of-care testing5→20
- Liquid biopsy2→13
- Point of care4→14
- Genomics1→7
- Detection limit1→6
- Liquid biopsy6→45
- Point-of-care testing23→49
- Biopsy2→24
- Internal medicine2→19
- Tuberculosis5→19
- Liquid biopsy1→16
- Point of care9→14
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1→5
- Point-of-care testing28→31
- Confidence interval2→5
Where diagnostics is researched across Switzerland
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.